HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.
暂无分享,去创建一个
N. Young | A. Barrett | J. Maciejewski | Y. Saunthararajah | J. Molldrem | F. Loberiza | R. Nakamura | T. Simonis | J. Nam | J. Robyn
[1] D. Follmann,et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. , 2001, Blood.
[2] N. Young,et al. Coincident myelodysplastic syndrome and T‐cell large granular lymphocytic disease: clinical and pathophysiological features , 2001, British journal of haematology.
[3] A. Raza,et al. Anti‐TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes , 2000, Microscopy research and technique.
[4] M. Okada,et al. Good response to cyclosporine therapy in patients with myelodysplastic syndrromes having the HLA-DRB1*1501 allele , 2000, Leukemia.
[5] Y. Saunthararajah,et al. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? , 2000, Seminars in hematology.
[6] A. Raza,et al. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. , 1999, Anticancer research.
[7] A. Barrett,et al. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte‐mediated inhibition of CFU‐GM and alterations in T‐cell receptor Vβ profiles , 1998, British journal of haematology.
[8] J. Čermák,et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow , 1998, British journal of haematology.
[9] N. Young,et al. Antithymocyte globulin for patients with myelodysplastic syndrome , 1997, British journal of haematology.
[10] N. Young,et al. The pathophysiology of acquired aplastic anemia. , 1997, The New England journal of medicine.
[11] J. G. van den Tweel,et al. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome , 1997, Cancer.
[12] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[13] H. Mizoguchi,et al. Response to immunosuppressive therapy and an HLA‐DRB1 allele in patients with aplastic anaemia: HLA‐DRB1*1501 does not predict response to antithymocyte globulin , 1996, British journal of haematology.
[14] N. Young,et al. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. , 1995, Blood.
[15] R. Peces,et al. Influence of HLA-DR phenotype on tumor necrosis factor-alpha production in renal-transplant recipients. , 1995, Nephron.
[16] H. Mizoguchi,et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. , 1994, Blood.
[17] M. Barnardo,et al. Improvements in HLA-C typing using sequence-specific primers (PCR-SSP) including definition of HLA-Cw9 and Cw10 and a new allele HLA-"Cw7/8v". , 1994, Tissue antigens.
[18] M. Dhodapkar,et al. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? , 1994, Blood.
[19] S. Nimer,et al. An Increased HLA DR2 Frequency Is Seen in Aplastic Anemia Patients , 1994 .
[20] M. Bunce,et al. Rapid DNA typing for HLA-C using sequence-specific primers (PCR-SSP): identification of serological and non-serologically defined HLA-C alleles including several new alleles. , 1994, Tissue antigens.
[21] S. Nimer,et al. An increased HLA DR2 frequency is seen in aplastic anemia patients. , 1994, Blood.
[22] S. Asano,et al. Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes. , 1993, International journal of hematology.
[23] K. Yoshinaga,et al. T cell‐mediated inhibition of erythropoiesis in myelodysplastic syndromes , 1992, American journal of hematology.
[24] J. Storek. Chronic neutrophilic leukemia: Case report documenting the absence of bcr‐abl rearrangement , 1992, American journal of hematology.
[25] M. Matsuda,et al. Increased production of tumor necrosis factor‐α by peripheral blood mononuclear cells in the patients with aplastic anemia , 1991, American journal of hematology.
[26] J. Smith,et al. The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. , 1991, Leukemia research.
[27] N. Morling,et al. Association between HLA‐DR2 and Production of Tumour Necrosis Factor α and Interleukin 1 by Mononuclear Cells Activated by Lipopolysaccharide , 1988, Scandinavian journal of immunology.
[28] H. Uchino,et al. Refractory myelodysplastic anaemias with hypocellular bone marrow. , 1988, Journal of clinical pathology.
[29] A. Gratwohl,et al. ANTILYMPHOCYTE GLOBULIN FOR MYELODYSPLASTIC SYNDROME? , 1988, British journal of haematology.
[30] A. Gratwohl,et al. Increased frequency of DR2 in patients with aplastic anaemia and increased DR sharing in their parents , 1986, British journal of haematology.
[31] P. McCullagh. Analysis of Ordinal Categorical Data , 1985 .
[32] G. Tricot,et al. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations , 1985, British journal of haematology.